PureTech's Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
Portfolio Pulse from Benzinga Newsdesk
PureTech Health's founded entity, Vedanta Biosciences, has dosed the first patient in a Phase 2 clinical trial of VE202 for the treatment of ulcerative colitis. The U.S. FDA has granted Fast Track designation to VE202, which is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need.
October 04, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PureTech Health's founded entity, Vedanta Biosciences, has begun a Phase 2 clinical trial of VE202 for ulcerative colitis treatment. The FDA has granted Fast Track designation to VE202, which could expedite its review process.
The news of the first patient being dosed in the Phase 2 clinical trial of VE202 and the Fast Track designation from the FDA are positive developments for PureTech Health. This could potentially expedite the review process of the drug, bringing it closer to market and potentially increasing PureTech's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100